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Purpose: Current methods for estimating and reporting radiation dose from CT examinations are
largely patient-generic; the body size and hence dose variation from patient to patient is not re-
flected. Furthermore, the current protocol designs rely on dose as a surrogate for the risk of cancer
incidence, neglecting the strong dependence of risk on age and gender. The purpose of this study
was to develop a method for estimating patient-specific radiation dose and cancer risk from CT
examinations.
Methods: The study included two patients a 5-week-old female patient and a 12-year-old male
patient, who underwent 64-slice CT examinations LightSpeed VCT, GE Healthcare of the chest,
abdomen, and pelvis at our institution in 2006. For each patient, a nonuniform rational B-spine
NURBS based full-body computer model was created based on the patient’s clinical CT data.
Large organs and structures inside the image volume were individually segmented and modeled.
Other organs were created by transforming an existing adult male or female full-body computer
model developed from visible human data to match the framework defined by the segmented
organs, referencing the organ volume and anthropometry data in ICRP Publication 89. A Monte
Carlo program previously developed and validated for dose simulation on the LightSpeed VCT
scanner was used to estimate patient-specific organ dose, from which effective dose and risks of
cancer incidence were derived. Patient-specific organ dose and effective dose were compared with
patient-generic CT dose quantities in current clinical use: the volume-weighted CT dose index
CTDIvol and the effective dose derived from the dose-length product DLP.
Results: The effective dose for the CT examination of the newborn patient 5.7 mSv was higher
but comparable to that for the CT examination of the teenager patient 4.9 mSv due to the
size-based clinical CT protocols at our institution, which employ lower scan techniques for smaller
patients. However, the overall risk of cancer incidence attributable to the CT examination was much
higher for the newborn 2.4 in 1000 than for the teenager 0.7 in 1000. For the two pediatric-aged
patients in our study, CTDIvol underestimated dose to large organs in the scan coverage by 30%–
48%. The effective dose derived from DLP using published conversion coefficients differed from
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409 Li et al.: Patient-specific CT dose and risk: Application to patients 409that calculated using patient-specific organ dose values by 57% to 13%, when the tissue weight-
ing factors of ICRP 60 were used, and by 63% to 28%, when the tissue weighting factors of ICRP
103 were used.
Conclusions: It is possible to estimate patient-specific radiation dose and cancer risk from CT
examinations by combining a validated Monte Carlo program with patient-specific anatomical
models that are derived from the patients’ clinical CT data and supplemented by transformed
models of reference adults. With the construction of a large library of patient-specific computer
models encompassing patients of all ages and weight percentiles, dose and risk can be estimated for
any patient prior to or after a CT examination. Such information may aid in decisions for image
utilization and can further guide the design and optimization of CT technologies and scan
protocols. © 2011 American Association of Physicists in Medicine. DOI: 10.1118/1.3515864
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NURBSI. INTRODUCTION
Since its introduction in the 1970s, computed tomography
CT has expanded its application areas from neurological
and oncological examinations in the early stage to examina-
tions of a wide range of disease conditions, including those
in young patients. With the expanding use of CT comes great
concern over its radiation exposure.1 By its nature, CT deliv-
ers substantially higher radiation dose to patients than con-
ventional radiography. Adding to the radiation burden are a
repeated or redundant examinations, b technical factors not
adapted to patient size, and c inconsistent use of technical
factors from time to time in the same patient. To effectively
manage CT radiation, it is highly desirable that the radiation
dose and potential cancer risk associated with each CT scan
of each patient be reported and documented. Such a patient-
specific dose and risk reporting system could guide the de-
sign of CT protocols, ensure consistent use of technical pa-
rameters, and aid in decisions for image utilization,
especially in situations where multiple examinations have
been performed or are being considered.
The current dose-reporting method, however, is patient-
generic; a patient’s dosimetry report only includes quality




































FIG. 1. Lifetime attributable risks of cancer incidence tabulated in BEIR VII
report Ref. 22. Risks for lung cancer and all cancers are shown to illustrate
the strong dependence of risk on age and gender.
Medical Physics, Vol. 38, No. 1, January 2011measured in a standard-size cylindrical phantom e.g., 32 cm
diameter phantom for adult body. While a myriad of
physical3,4 and computerized5–10 anthropomorphic phantoms
exist for dosimetric applications, they only represent stan-
dard or limited patient sizes at discrete reference ages e.g.,
0, 1, 5, 10, and 15 years of age and do not reflect the size
and hence dose variation from patient to patient. Further-
more, the current protocol designs rely on dose as a surrogate
for the risk of cancer incidence, neglecting the fact that the
same dose delivered to two patients may entail substantially
different risks due to age and gender differences. Figure 1
illustrates the strong dependence of risk on age and gender
using lung cancer and all cancers combined as examples.
In Part I of this work see Ref. 47, we reported the de-
velopment of a Monte Carlo program for simulating dose
from CT examinations and the validation of this program in
cylindrical and anthropomorphic phantoms for both axial and
helical scans. The goal of this paper was to apply this pro-
gram to actual patients to develop a method for patient-
specific dose and risk estimation.
II. MATERIALS AND METHODS
II.A. Patients
The study included two patients: A newborn 5 weeks,
female and a teenager 12 years, male. Both patients under-
went 64-slice CT examinations LightSpeed VCT, GE
Healthcare, Waukesha, WI of the chest, abdomen, and pelvis
at our institution in 2006 using our size-based pediatric pro-
tocols at the time that employed fixed tube currents Table I.
The study was approved by our institutional review board
IRB, who determined that it was in compliance with the
Health Insurance Portability and Accountability Act
HIPAA, and did not require informed consent.
II.B. Patient-specific computer models
For each patient, a full-body computer model was created
from the patient’s clinical CT data. The initial anatomy of the
model was defined by segmenting the patient’s CT images
using a software application developed in our laboratory. The
heart, liver, gall bladder, stomach, spleen, and kidneys were
410 Li et al.: Patient-specific CT dose and risk: Application to patients 410manually segmented by contouring from each CT slice. The
lungs and bones were semiautomatically segmented using
CT number thresholding. Once a data set was segmented,
three-dimensional polygon models were generated for each
structure using the marching cubes algorithm.11,12 Three-
dimensional NURBS surfaces were then fitted to the polygon
models using NURBS modeling software Rhinoceros, Mc-
Neel North America, Seattle, WA to create the initial
patient-specific model.
Other organs and structures, not easily segmented or vis-
ible in the scan coverage, were defined by morphing an ex-
isting male or female full-body adult model developed from
visible human data13 to match the framework defined by the
segmented organs. The morphing was performed manually
using the affine transformations of rhinoceros. The volumes
of the organs and structures defined in this manner were
checked and scaled, if necessary, to match age-interpolated
organ volume and anthropometry data in ICRP Publication
89.19 More details on the process of model creation is re-
ported in another publication.14
The full-body models of the newborn female and the teen-
ager male patients possessed a total of 44 and 43 organs,
respectively, including most of the radiosensitive organs de-
fined by ICRP Publication 103 Ref. 15 Table II. Figure 2
illustrates surface-rendered views of the three-dimensional
anatomy in the computer models of the two patients.
While each patient’s three-dimensional CT data set may
also serve as his/her patient-specific computer model,16 the
full-body models in our study allowed dose to be estimated
for not only organs within the image volume, but also organs
in the overranging distance additional scan length necessary
for data interpolation in helical reconstruction17 and those
outside the scan coverage.
II.C. Organ dose simulations
The NURBS model of each patient was “positioned” on a
model of the CT table see Part I of this work in a supine
position with arms elevated above the head to mimic actual
TABLE I. CT examinations undergone by the two patients in our study.
consisting of a chest scan and an abdomen-pelvis scan.
Newborn 5 weeks, femal
Chest Abdom
Image coverage From lung apex






Gantry rotation period s 0.4
Scan FOV bowtie filter Pediatric body small Pediatric
Collimation mm 40
Pitch 0.984 0
Slice thickness mm 3.75 3
Reconstruction interval mm 2.5
Overranging distance cm 4.72 4patient posture during CT examinations. The models were
Medical Physics, Vol. 38, No. 1, January 2011voxelized at 0.5 and 1 mm isotropic resolutions for the new-
born and the teenager, respectively. Each organ/structure was
assigned a material Table II based on the elemental com-
position and mass density information tabulated in ICRU
Publication 46 Ref. 18 with the exception of the skeleton a
homogeneous mixture of its component tissues, for which
the material information published by Cristy and Eckerman5
for the skeletons of newborn and adult was used for the
newborn and the teenager patients, respectively.
For each patient, organ dose simulation was performed for
the chest scan and the abdomen-pelvis scan separately Table
I. The dose from the entire examination was then calculated
as the sum of the dose from the two scans. The scan cover-
age in the actual patient examinations Table I was repro-
duced in the simulations. The total scan length in a helical
scan was calculated as the image coverage plus the overrang-
ing distance Table I. The overranging distance was esti-
mated from the scanner console parameters as “table speed
cm /s total scan time s–image coverage cm.” In a he-
lical scan, the x-ray tube starting angle is not fixed and thus
different each time per private communication with the
manufacturer. As the exact tube starting angles in the pa-
tients’ examinations were unknown part of CT raw data, not
archived, each scan was simulated six times with the tube
starting angle differing by 60º each time.
Energy deposited in organs and tissues was tallied and
used to calculate dose. Because bone marrow and bone sur-
face were not explicitly modeled, the following methods
were used to estimate dose to these two organs. To assess
dose to the red bone marrow, volume-averaged photon flu-
ence spectrum was tallied individually at each skeletal site
and used to calculated dose to the red bone marrow via the
fluence-to-dose conversion coefficients published by Cristy
and Eckerman.5 A single active marrow dose was then cal-
culated as its skeletal average using the age-dependent frac-
tional distribution of active marrow tabulated in ICRP Pub-
lication 89.19 Dose to the bone surface was approximated by
the mass-weighted average of dose to the homogenous bones
20
patient underwent a combined chest-abdomen-pelvis CAP examination





From 1 cm above lung apex
to top of liver
From 1 cm above top
























.72as recommended by Lee et al.
411 Li et al.: Patient-specific CT dose and risk: Application to patients 411TABLE II. Summary of organs in the computer models of the two patients.
Organ/structure
Density
g cm−3 h Material ICRU 46h
Mass gj
Newborn 5 weeks, female Teenager 12years, male
Respiratory system
Pharynx-larynxa 1.03 Average soft tissuei 1.6 17.3
Trachea-bronchi 1.03 Average soft tissue 1.0 13.7
Lungs 0.26 Lung adult, healthy, inflated 57.9 445.3
Alimentary system
Esophagus 1.03 Average soft tissue 1.5 18.0
Stomachb 1.03 Average soft tissue 39.4 282.9
Pancreas 1.03 Average soft tissue 9.2 82.1
Liver 1.03 Average soft tissue 104.5 961.5
Gall bladder 1.03 Average soft tissue 4.1 24.6
Small intestine 1.03 Average soft tissue 70.7 558.3
Large intestine 1.03 Average soft tissue 63.9 436.5
Circulatory system
Heart 1.03 Average soft tissue 51.2 459.8
Urogenital system
Kidneys 1.03 Average soft tissue 21.5 189.3
Urinary bladder 1.03 Average soft tissue 5.4 63.8
Prostatec 1.03 Average soft tissue – 3.1
Testes 1.03 Average soft tissue – 3.9
Ovaries 1.03 Average soft tissue 0.5 –
Uterus 1.03 Average soft tissue 3.2 –
Vagina 1.03 Average soft tissue 0.4 –
Skeletal systemd
Cranium 1.4h Average skeletonh 257.5 941.9
Mandible 1.4 Average skeleton 20.5 99.4
Clavicles 1.4 Average skeleton 1.2 42.9
Scapulea 1.4 Average skeleton 6.3 164.6
Sternum 1.4 Average skeleton 2.5 32.1
Ribs 1.4 Average skeleton 25.5 302.9
Cervical vertebrae 1.4 Average skeleton 7.1 74.4
Thoracic vertebrae 1.4 Average skeleton 23.5 233.7
Lumbar vertebrae 1.4 Average skeleton 16.6 186.7
Pelvis 1.4 Average skeleton 25.6 492.6
Sacrum 1.4 Average skeleton 10.9 152.7
Upper humeri 1.4 Average skeleton 5.1 175.9
Lower humeri 1.4 Average skeleton 3.7 125.1
Radii, ulnae 1.4 Average skeleton 6.1 185.9
Wrist and hand bones 1.4 Average skeleton 4.6 132.1
Upper femora 1.4 Average skeleton 10.9 439.6
Lower femora 1.4 Average skeleton 15.0 543.9
Tibiae, fibiae, patellae 1.4 Average skeleton 21.5 765.5
Ankle and foot bones 1.4 Average skeleton 12.1 420.1
Integumentary system
Skin torso onlye 1.03 Average soft tissue 49.3 452.4
Additional organs/tissues
Brain 1.03 Average soft tissue 400.3 1488.4
Eyes 1.03 Average soft tissue 6.8 14.6
Thyroid 1.03 Average soft tissue 1.6 11.2
Breastsf 0.96 Breast 50/50 0.7 2.2
Thymus 1.03 Average soft tissue 16.3 37.5
Spleen 1.03 Average soft tissue 8.1 215.1
Adrenal glands 1.03 Average soft tissue 6.5 10.6
Residual soft tissuesg 1.03 Average soft tissue 2348.2 30 226.5
aCombined organ of pharynx and larynx, combined organ of trachea and bronchi, and esophagus were modeled as tubular organs with air-fill lumens. The wall
thickness of these tubular organs was assumed to be 2 mm for the newborn and 3 mm for the teenager. It was independently verified that, over the range of
1–3 mm, the effect of wall thickness on organ dose was less than 1%. Dose to combined organ of pharynx and larynx was used as a surrogate for dose to
salivary glands, oral mucosa, and extrathoracic ET region.
bAlimentary tract organs stomach, small intestine, large intestine, heart, gall bladder, and urinary bladder were modeled as single homogenous organs without
Medical Physics, Vol. 38, No. 1, January 2011
412 Li et al.: Patient-specific CT dose and risk: Application to patients 412In terms of simulation time, using a single processor on a
2.3 GHz Linux server with 20 GB of random access memory
RAM, 80 million photon histories 6 h runtime plus an-
other 30 min of input/output operation time were used to
simulate each CT scan of each patient, resulting in relative
dose error of less than 1% for all organs in the scan coverage
and less than 3% for other organs.
II.D. Effective dose and cancer risk calculations
Simulated organ dose values were used to calculate effec-
tive dose for each CT scan of each patient as
delineation of walls and contents. For alimentary tract organs, dose to t
radiosensitive wall lining. This is a reasonable approximation since the wal
cProstate, testes, ovaries, uterus, and vagina are gender-specific organs and
dThe skeleton was modeled as a homogeneous mixture of its component ti
various connective tissues. The atomic composition and mass density data p
were used for the newborn and the teenager patients, respectively.
eThe torso of the NURBS model of each patient was covered with a skin lay
1 and 2 mm for the newborn and the teenager patients, respectively, resulting
skin dose was calculated as torso skin dose multiplied by the ratio of torso
NURBS model of each patient.
fThe breasts of each patient were located based on the body surface contours
They were modeled as homogenous organs with elemental composition d
glandular breast tissue only starts developing in puberty Ref. 46, the breas
the BEIR VII report Ref. 22, the lifetime attributable risk of breast cancer
radiosensitive structure, the dose to which was approximated by the dose to
gResidual soft tissues included skeletal muscle, adipose tissue, cartilage, blo
used to approximate dose to skeletal muscle and lymphatic nodes.
hThe atomic composition and mass density data tabulated in ICRU Publica
skeleton see footnote d.
iAverage soft tissue of adult male was used.
jOrgan/tissue mass in the voxel models.
FIG. 2. Surface rendered views of the three-dimensional anatomy in the
computer models of the newborn female 5 weeks old, left and the teenager
male 12 years old, right patients in this study.
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T
wTHT, 1
where HT is the equivalent dose for organ/tissue T and wT is
the tissue weighting factor defined by ICRP Publication
103.15 Dose to radiosensitive organs that were not explicitly
modeled was approximated by dose to neighboring organs
Table II. Dose to the testes or the ovaries was used as dose
to the gonads. The wT for the reminder tissues was applied to
the arithmetic mean dose of the 13 remainder tissues of each
gender. Breast dose was included in the calculation of effec-
tive dose for both patients.
While widely used as a surrogate for radiation risk, effec-
tive dose does not reflect individual patient risk; the tissue
weighting factors are mean values representing averages
over both gender and age.15 Therefore, to more accurately
estimate individual patient risks, we further implemented a
metric of risk, termed “risk index,” and defined as
risk index = 
T
rTgender, ageHT, 2
where rT is the gender-, age-, and tissue-specific risk coeffi-
cient cases/100 000 exposed to 0.1 Gy for lifetime attribut-
able risk of cancer incidence. The metric of risk index RI
presented here was adopted from the recently proposed con-
cept of effective risk.21 We chose to use the term risk index,
as opposed to effective risk, to reflect the inherent uncertain-
ties associated with estimating risks for individual patients,
who might have different radiosensitivities due to genetic
predispositions or hormonal profiles.
Values of rT are available for leukemia and for cancers of
eight to nine high-risk organs of each gender at discrete ages
of 0, 5, 10, 15, 20, 30, 40, 50, 60, 70, and 80 years,22 from
which we linearly interpolated the values of rT at other ages.
Cancers of other radiosensitive organs share a collective risk
coefficient rother.
22 The collective risk to these other organs
23
tire organ wall and content was used to approximate the dose to the
the content are located in parallel to each other.
included in the models of their respective genders only.
, namely, cortical bone, trabecular bone, yellow marrow, red marrow, and
ed by Cristy and Eckerman Ref. 5 for the skeletons of newborn and adult
allow dose estimations for the skin. The skin thickness was assumed to be
1–2 voxel definition of the skin in the Monte Carlo simulations. Whole body
area to whole body skin area, where skin areas were estimated from the
e patient in his/her CT images and relative to the locations of other organs.
d according to the 50/50-breast in ICRU Publication 46 Ref. 18. Since
the newborn patient were likely to have little glandular tissue; however, in
highest at age of zero. Thus, even the breast tissue of a newborn has some
/50-breast.
ymphatic tissues, and connective tissues. Dose to residual soft tissues was
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= rotherTother organswTHTTother organswT 	 , 3
where the other radiosensitive organs included heart, kidney,
gall bladder, spleen, pancreas, adrenal glands, thymus, small
intestine, salivary glands, extrathoracic region, lymph node,
muscle, oral mucosa, bone surface, brain, skin, testes male
only, and esophagus. Among these organs, the reminder tis-
sues, as defined by ICRP Publication 103,15 were each as-
signed a tissue-weighting factor of 0.01. As the individual rT
values for these “other organs” are unavailable, in Eq. 3,
we assumed that the contribution of each rT to the collective
rother is proportional to the sex- and age-averaged radiosen-
sitivity of organ T relative to all the other organs, as repre-
sented by ratio of the tissue weighting factors.
To compare patient-specific dose estimation with the cur-
rent dose-reporting method, dose to large organs inside the
scan coverage were compared with volume-averaged CTDI
CTDIvol.
24 Furthermore, effective dose calculated using the
organ dose of specific patients was compared with the effec-
tive dose derived from the dose-length product DLP.24 For
each patient’s each CT scan, CTDIvol was calculated from the
technical reference manual of the LightSpeed VCT scanner
using the tables of CTDI100 and technique adjustment fac-
tors. The scan FOV used for each patient Table I deter-
mined the corresponding CTDI phantom size: 16 cm diam-
eter and 32 cm diameter phantoms for the newborn and the
teenager patients, respectively. When calculating DLP, the
total scan length included the overranging distance. The
CTDIvol and DLP values calculated in this way agreed with
those from patients’ dosimetry reports to within about 5%.
To convert from DLP to effective dose, we used the conver-
sion coefficients often referred to as the k factors published
by Shrimpton et al.,25,26 which are the most frequently used
conversion coefficients in the literature27,28 and are included
in the AAPM Report No. 26.24 The conversion coefficients
for 0-year-old patients chest scan: k=0.039; abdomen-pelvis
scan: k=0.049 and 10-year-old patients chest scan: k
=0.013; abdomen-pelvis scan: k=0.015 were used for the
newborn and the teenager patients in this study, respectively.
Considering that these conversion coefficients were devel-
oped based on the older ICRP Publication 60,29 effective
dose was also calculated using the tissue weighting factors of
ICRP Publication 60. This allowed the difference between
patient-specific and patient-generic dose estimations to be
demonstrated without the confounding effect of the change
in tissue weighting factors.
Lastly, we assessed the need for creating a full-body com-
puter model for dose and risk estimations, i.e., the need for
modeling organs and structures outside of the image cover-
age. For simplicity, the effective dose and risk index were
recalculated with dose and risk to organs completely outside
Medical Physics, Vol. 38, No. 1, January 2011of the image coverage set to zero. While doing so was not
identical to performing dose simulations with partial-body
computer models based entirely on the patients’ clinical CT
data, it provided a rough assessment of the need for model-
ing organs and structures outside of the image coverage.
III. RESULTS
Examples of dose distributions in the two patients from
their CT examinations are illustrated in Fig. 3. The dose
distribution was more uniform in the newborn patient pitch
of 0.984 than in the teenager patient pitch of 1.375. As a
result of the overranging distance, a large portion of the ab-
domen chest was irradiated in the chest abdomen-pelvis
scan.
Table III summarizes the organ and effective dose values.
The corresponding risks of cancer incidence are tabulated in
Table IV. For the newborn patient, lung dose from the
abdomen-pelvis scan was comparable to that from the chest
scan Table III. For both patients, the effective dose from
the abdomen-pelvis scan was close to double that from the
chest scan. For the entire chest-abdomen-pelvis examination
consisting of a chest scan and an abdomen-pelvis scan, the
organ and effective dose of the newborn patient was one to
two times that of the teenager patient Table III, last column.
However, the newborn patient had about ten times greater
risk of thyroid cancer than the teenager patient Table IV,
last column. The risk index overall cancer risk of the new-











(a) (b) (c) (d)
FIG. 3. Coronal dose distributions in the two patients, resultant from their
CT examinations: a chest scan of the newborn patient, b abdomen-pelvis
scan of the newborn patient, c chest scan of the teenager patient, and d
abdomen-pelvis scan of the teenager patient. The tube starting angle was 0°
12 o’clock for all scans. The coronal plane was taken about half-way in
between the anterior and posterior surfaces of each patient. The computer
model of each patient with organs shown on a gray scale was overlaid with
a semitransparent colored image of the dose distribution. The noise in the
dose distribution is reflective of the limited number of photos used in the
simulations. As organ dose was an average over the entire organ volume, the
uncertainty associated with organ dose was less than 1% for all organs in the
scan coverage and less than 3% for other organs see Sec. II C.Table IV, last column.
414 Li et al.: Patient-specific CT dose and risk: Application to patients 414For most organs, the dose uncertainty due to the random
tube starting angle was less than 10% Table III. The uncer-
tainty was generally higher at pitch of 1.375 compared to
pitch of 0.984. The uncertainty was higher for small periph-
eral organs e.g., breast, testes and for organs on the edge of
the scan coverage e.g., gall bladder in the chest scan of the
newborn patient; pharynx-larynx, stomach, liver, kidney,
spleen in the chest scan of the teenager patient; breasts in the
abdomen-pelvis scans of both patients. Tube starting angle
TABLE III. Organ and effective dose of the two patients from their CT e
examination consisting of a chest scan and an abdomen-pelvis scan. Each do
bracket is the coefficient of variation standard deviation100% /average
Newborn 5 weeks, female
Chest Abdomen-pelvis C
Respiratory system
Pharynx-larynx 1.86 5%c 0.23 1% c,d 2
Trachea-bronchi 3.28 0% 0.58 2% c,d 3
Lungs 3.68 0% 3.54 3% 7
Alimentary system
Esophagus 3.20 0% 1.55 3% c 4
Stomach 1.36 7% c 6.36 0% 7
Pancreas 0.34 2% c,d 6.38 1% 6
Liver 2.02 8% c 6.56 0% 8
Gall bladder 1.02 16%c 6.88 1% 7
Small intestine 0.27 4% c 7.07 0% 7
Large intestine 0.24 7% c 6.76 0% 7
Circulatory system
Heart 3.56 0% 4.16 7% 7
Urogenital system
Kidneys 1.52 8% c 6.08 0% 7
Urinary bladder 0.04 3% c,d 6.30 2% 6
Prostate - -
Testes - -
Ovaries 0.05 5%c,d 6.28 2% 6
Uterus 0.04 2% c,d 6.18 2% 6
Vagina 0.03 5% c,d 6.24 2% 6
Skeletal system
Bone surface 1.81 2% 3.36 0% 5
Red bone marrow 0.83 1% 1.57 0% 2
Integumentary system
Skin 0.54 1% 1.70 1% 2
Additional organs/tissues
Brain 0.12 1% c,d 0.05 1% c,d 0
Eyes 0.08 7% c,d 0.03 2% c,d 0
Thyroid 2.85 1% 0.36 3% c,d 3
Breasts 2.88 1% 1.62 31% c 4
Thymus 3.53 0% 0.73 3% c 4
Spleen 2.63 3% 5.79 1% 8
Adrenal glands 2.04 2% 6.05 0% 8
Residual soft tissues 0.99 1% 2.81 1% 3
Effective dose mSv 1.64 1% 4.04 2% 5
aDose from the combined chest-abdomen-pelvis CAP examination, i.e., the
bDose ratio equals dose to the newborn patient from her CAP examination
cOrgans completely outside of the image coverage Table I.
dOrgans completely outside of the scan coverage scan coverage equals imahad a small effect on effective dose and risk index 5%.
Medical Physics, Vol. 38, No. 1, January 2011For the two pediatric-aged patients in this study, CTDIvol
underestimated dose to large organs in the scan coverage by
30%–48% Table V. The effective dose derived from DLP
differed from that estimated using patient-specific organ dose
values by 57% to 13%, when the tissue weighting factors
of ICRP 60 were used and by 63% to 28%, when the tissue
weighting factors of ICRP 103 were used Table V. Com-
pared with ICRP 103 based effective dose, ICRP 60 based
effective dose was 15%–16% lower for chest scans, but
ations. Each patient underwent a combined chest-abdomen-pelvis CAP
lue is the average over six tube starting angles. The percentage value in the
s tube starting angles.
e mGy
Dose ratiobTeenager 12 years, male
Chest Abdomen-pelvis CAPa CAP
1.03 17% c 0.06 3% c,d 1.09 1.9
3.88 3% 0.38 2% c,d 4.26 0.9
3.93 0% 2.54 2% 6.47 1.1
3.35 2% 1.37 1% 4.72 1.0
1.53 17% c 5.04 1% 6.57 1.2
0.55 4% c,d 4.91 1% 5.46 1.2
1.57 13%c 4.93 0% 6.50 1.3
0.37 9%c,d 5.52 8% 5.89 1.3
0.15 4%c,d 5.57 1% 5.72 1.3
0.10 3% c,d 5.08 1% 5.18 1.4
4.14 1% 2.61 10% 6.75 1.1
0.75 11% c 4.52 0% 5.27 1.4
0.02 2% c,d 5.20 3% 5.22 1.2
0.01 5% c,d 4.05 2% 4.06 -
0.00 14% c,d 5.10 15% 5.10 -
- - - -
- - - -
- - - -
1.45 1% 2.68 0% 4.13 1.3
1.01 1% 1.91 0% 2.92 0.8
0.60 1% 1.24 0% 1.84 1.2
0.07 2%c,d 0.01 3% c,d 0.08 2.1
0.05 3%c,d 0.01 8% c,d 0.06 1.8
4.47 10% 0.23 2% c,d 4.70 0.7
3.64 23% 1.04 42% c 4.68 1.0
4.05 4% 0.51 4% c,d 4.56 0.9
1.60 18% 4.60 1% 6.20 1.4
1.29 4%c 4.07 2% 5.36 1.5
0.73 0% 1.44 0% 2.17 1.8
1.78 5% 3.15 1% 4.93 1.2
mation of dose from the chest scan and that from the abdomen-pelvis scan.
dose to the teenager patient from his CAP examination.





































ge co14%–16% higher for abdomen-pelvis scans.
415 Li et al.: Patient-specific CT dose and risk: Application to patients 415Excluding the dose to organs completely outside of the
image coverage resulted in an underestimation of effective
dose by 4%–22% Table VI. The underestimation was
smaller for abdomen-pelvis scans. Excluding the risks to or-
gans completely outside of the image coverage resulted in an
underestimation of risk index by 0%–19% Table VI. The
underestimation was the largest for the abdomen-pelvis scan
of the female newborn patient due to the exclusion of
breast cancer risk.
IV. DISCUSSION
In this study, we demonstrated that it is possible to esti-
mate patient-specific radiation dose and cancer risk from CT
examinations by combining a validated Monte Carlo pro-
gram with patient-specific anatomical models that are de-
rived from the patients’ clinical CT data and supplemented
by transformed models of reference adults. While patient-
specific dose estimations have been pursued in the past, they
were either limited to providing dose for only the imaged
part of the body16,30 or limited to patients whose cadavers
had undergone a whole-body scan.31 Although the dose and
risk estimates reported in our study were strictly patient-
specific only for the segmented organs inside the image vol-
ume, as these organs receive the highest dose, the resultant
effective dose and risk index estimates were indicative of the
specific patients in their entirety.
For the newborn patient, lung dose from the abdomen-
pelvis scan was comparable to those from the chest scan
Table III due to both the overranging distance and the
higher technique higher kVp and mA used in the abdomen-
pelvis scan. For both patients, the effective dose from the
TABLE IV. Lifetime risks of cancer incidence for the two patients attributable
consisting of a chest scan and an abdomen-pelvis scan. Each risk value is th
coefficient of variation standard deviation100% /average across tube sta
Lifetime attributable risk o
Newborn 5 weeks, female
Chest Abdomen-pelvis C
Thyroid Bancer 0.179 1% 0.023 3% c,d 0
breast cancer 0.335 1% 0.189 31% c,d 0
Lung cancer 0.269 0% 0.259 3% 0
Stomach cancer 0.014 7% c 0.064 0% 0
Liver cancer 0.006 8% c 0.018 0% 0
Colon cancer 0.005 7% c,d 0.148 0% 0
Bladder cancer 0.001 3% c,d 0.133 2% 0
Prostate cancer - - - -
Ovary cancer 0.001 5% c,d 0.065 2% 0
Uterus cancer 0.000 2% c,d 0.031 2% 0
Leukemia 0.015 1% 0.029 0% 0
Other cancer 0.250 1% 0.403 1% 0
Risk index 1.075 0% 1.361 5% 2
aRisk from the combined chest-abdomen-pelvis CAP examination, i.e., the
bRisk ratio equals risk to the newborn patient from her CAP examination o
cCancer risks to organs that were completely outside of the image coverage
dCancer risks to organs that were completely outside of the scan coverage.abdomen-pelvis scan was close to double that from the chest
Medical Physics, Vol. 38, No. 1, January 2011scan. This can be attributable to the higher technique kVp
and/or mA and the larger irradiated body volume in the
abdomen-pelvis scan.
It is generally accepted that when the same scan technique
is used, a smaller patient receives higher radiation dose.31,32
Due to the size-based pediatric CT protocols in use at our
institution, which use lower scan techniques for smaller pa-
tients, organ and effective dose received by the newborn pa-
tient was comparable to that of the teenager patient Table
III, last column. However, when the risks of cancer inci-
dence were assessed, the newborn patient had about ten
times greater risk of thyroid cancer than the teenager patient
Table IV, last column due to age and gender differences.
The risk index overall cancer risk of the newborn patient
was about four times that of the teenager patient Table IV,
last column. As the same dose may entail substantially dif-
ferent risks to patients of different ages and genders, patient-
specific risk estimates should be used together with dose
estimates to guide the design and optimization of CT tech-
nologies and scan protocols. Knowledge of the risks to a
specific patient may potentially influence the decisions for
image utilization, especially in situations where multiple ex-
aminations are being performed or considered. Furthermore,
patient-specific risk information may be extremely helpful
for institutional review of scientific investigations using CT
examinations. Finally, patient-specific dose and risk estima-
tions afford more individualized and expanded application of
dose tracking from medical radiation exposures.33,34
Our study showed that the dose distribution was more
uniform in the newborn patient pitch of 0.984 than in the
teenager patient pitch of 1.375. As a result, the dose uncer-
eir CT examinations. Each patient underwent a combined CAP examination
rage over six tube starting angles. The percentage value in the bracket is the
angles.
cer incidence cases/1000 exposed
Risk
ratiobTeenager 12 years, male
Chest Abdomen-pelvis CAPa CAP
0.020 10% 0.001 2% c,d 0.021 9.6
- - - - - -
0.080 0% 0.052 2% 0.132 4.0
0.008 17%c 0.026 1% 0.034 2.3
0.006 13%c 0.020 0% 0.026 0.9
0.002 3%c,d 0.117 1% 0.119 1.3
0.000 2% c,d 0.074 3% 0.074 1.8
0.000 5% c,d 0.026 2% 0.026 -
- - - - - -
- - - - - -
0.012 1% 0.022 0% 0.034 1.3
0.055 2% 0.143 8% 0.198 3.3
0.184 1% 0.481 2% 0.665 3.7
mation of risk from the chest scan and that from the abdomen-pelvis scan.





















tainty due to the random tube starting angle was generally
416 Li et al.: Patient-specific CT dose and risk: Application to patients 416larger at pitch of 1.375 Table III. However, one should not
interpret this result as “the lower the helical pitch, the more
uniform the dose distribution, and hence the smaller the ef-
fect of tube starting angle.” At a pitch less than unity, the hot
spots created by beam overlap can also lead to nonuniform
dose distribution along the z-axis.35 The effect of tube start-
ing angle was reduced by the presence of scattered radiation.
As peripheral/surface organs received lower scattered radia-
tion compared to central organs, the dose uncertainty was
higher for peripheral organs, especially small peripheral or-
gans e.g., breasts and testes. The effect of tube starting
angle was also found to be large for organs on the edge of the
scan coverage e.g., gall bladder in the chest scan of the
newborn patient; pharynx-larynx, stomach, liver, kidney,
spleen in the chest scan of the teenager patient, breasts in the
abdomen-pelvis scans of both patients. This can be ex-
plained both by the uncertainty in the fraction of organ vol-
TABLE V. Comparison between volume-weighted CT
comparison between effective dose derived from D
dose estimated using patient-specific organ dose valu
New
Ch
Large organ dose mGy a
Approximated by CTDIvol
b 2.21
Estimated for specific patient 3.62
Discrepancy 39%
Effective dose mSv
Derived from DLPc 1.18
Estimated for specific patient ICRP 103 1.64
Estimated for specific patient ICRP 60 1.37
Discrepancy DLP VS ICRP 103 28%
Discrepancy DLP VS ICRP 60 14%
Discrepancy ICRP 60 VS ICRP 103 16%
aAverage dose to large organs inside the scan covera
liver and small intestine for the abdomen-pelvis scan
bThe scan FOV used for each patient Table I de
diameter and 32 cm diameter phantoms for the newb
cThe DLP was 30.34 and 105.77 mGy- cm for ches
51.14 and 104.99 mGy- cm for chest and abdomen-p
TABLE VI. Comparison between effective dose and ri




Include all radiosensitive organs 1.64
Include only imaged radiosensitive organsa 1.28
Discrepancy 22
Risk index cases/1000 exposed
Include all radiosensitive organs 1.07
Include only imaged radiosensitive organsa 0.99
Discrepancy 8%
aExclude dose and risk to organs that were completel
and IV
Medical Physics, Vol. 38, No. 1, January 2011ume covered by the primary radiation and the low scattered
radiation from neighboring organs outside of the scan cover-
age.
To further demonstrate the inadequacy of the current
patient-generic dose reporting method, we compared CTDIvol
with patient-specific dose to large organs in the scan cover-
age. For the two patients in our study, CTDIvol grossly un-
derestimated 30% to 48% dose to large organs in the
scan coverage, primarily because the newborn and the teen-
ager patients had average trunk diameters of 9.7 and 21.7
cm, respectively, much smaller than the diameters of the
standard CTDI phantoms i.e., 16 and 32 cm diameter
PMMA or equivalently 18 and 36 cm diameter water36, on
which the respective CTDIvol values were based. As such,
CTDIvol should not be used as a surrogate for patient dose in
CT.
Furthermore, we showed that the effective dose derived
index CTDIvol and patient-specific organ dose, and
ing published conversion coefficients and effective











epresented by lung and heart for the chest scan and
ed the corresponding CTDI phantom size: 16 cm
nd the teenager patients, respectively.
abdomen-pelvis scans of the newborn patient, and
scans of the teenager patient.
ex calculated using dose to all radiosensitive organs
tive organs.


























417 Li et al.: Patient-specific CT dose and risk: Application to patients 417from DLP can differ substantially from that calculated using
patient-specific organ dose values, even when the tissue
weighting factors of ICRP 60 were used. The DLP-to-
effective dose conversion coefficients k factors of
Shrimpton et al.25,26 were developed based on ICRP 60 and a
family of mathematical/stylized reference phantoms devel-
oped by Cristy and Eckerman.5 The 0-year-old and the 10-
year-old reference phantoms in this family had equivalent
trunk diameters of 11.2 and 21.6 cm, respectively, compa-
rable to the body size of the newborn and the teenager pa-
tients in this study, who had average trunk diameters of 9.7
and 21.7 cm, respectively. The discrepancies in effective
dose found for the newborn patient chest scan: 14%;
abdomen-pelvis scan: 13% were most likely due to the dif-
ferences in anatomy between the newborn patient and
0-year-old reference phantom. The latter had a trunk defined
by an elliptical cylinder with organs defined by simple geo-
metric shapes. The particular large discrepancies in effective
dose found for the teenager patient chest scan: 56%;
abdomen-pelvis scan: 57% can be attributed to yet an-
other factor: the mismatch in CTDI phantom. The teenager
patient in our study was scanned using the medium body
scan field-of-view, which corresponded to a 32 cm diameter
CTDI phantom, whereas all the k factors for pediatric pa-
tients were developed assuming CTDI values in a 16 cm
diameter phantom. Thus, the k factors for pediatric patients
can significantly underestimate effective dose, if the pediatric
patient is not scanned using a scan field-of-view type that
corresponds to a 16 cm diameter CTDI phantom.
We found that effective dose based on organ dose and the
tissue weighting factors of ICRP 60 differ relative to ICRP
103 values by 15% to 16% for chest scans and by 14%–
16% for abdomen-pelvis scans. Similar discrepancies have
also been reported by other authors28 and are attributable to
the increase in breast weighting factor from 0.05 to 0.12 and
decrease in gonad weighting factor from 0.20 to 0.08.
Our study also quantified the changes in effective dose
4%–22% and risk index 0%–19% when dose and risk to
organs outside of the image coverage are assumed to be zero
Table VI. It may be argued that, for the abdomen-pelvis
scan of the teenager patient, the changes in effective dose
4% and risk index 0% are in consequential. However, as
many patients undergo sequential CT examinations over an
extended period of time, small underestimations can accu-
mulate and result in significant dose and risk errors. The
results highlight the importance of developing full-body pa-
tient models for dose and risk estimations.
It is important to note that in this study we did not use the
concept of effective dose as originally defined. Effective
dose was defined by ICRP for a reference hermaphrodite
adult; the tissue weighting factors are gender- and age-
averaged values, and the organ dose should be gender-
averaged values as well.15 Thus, in principle, effective dose
is not suitable for individual patients. However, the concept
has been widely applied to patients of various sizes, ages,
and genders27,31,37 and to individual patients.31 Recently, the
limitations of effective dose have been discussed in the lit-
erature, and there have been intensive debates over whether
Medical Physics, Vol. 38, No. 1, January 2011the concept is applicable to medical exposure and whether it
should be replaced.21,38–41 Our calculation of effective dose
using patient-specific organ dose values, while not being ex-
actly as defined by ICRP, served two purposes: a it pro-
vided patient dose estimates using a concept that the medical
imaging community is currently familiar with and thus can
put in context with other dose studies and b it approximates
the effective dose to a patient population including both
genders who has similar anatomy and body habitus as the
patient whose organ dose values were used in the effective
dose calculation.
The patient-specific method developed in this study can
be applied to report and document CT radiation in the fol-
lowing three foreseeable manners.
a With the development of a library of representative
patient-specific computer models, the method reported
in this study can be employed to create a database of
dose and risk estimates for patients of all ages and
weight percentiles. The database can then be used to
estimate patient-specific dose and risk for any new pa-
tient by matching the patient to an existing patient in
the library based on age, gender, and body habitus.
b An alternative to the first approach, the database of
dose and risk estimates can be used to draw correla-
tions between dose/risk, patient size/age/gender, and
technical factors, i.e.,
dose = ftechnical factors, patient size , 4
risk
= gtechnical factors, patient size, age, gender .
5
In a preliminary study of pediatric chest CT
examinations,42 we showed that dose to large organs in
the scan coverage is strongly correlated with the mid-
chest equivalent diameter of a patient r=−0.93 to
−0.99. Such correlations likely exist for a wider
range of patient sizes and for other body sections.
Furthermore, other investigators have demonstrated,
with small numbers of patients and scanner models,
that when organ dose simulated by Monte Carlo
methods are normalized by CTDI values, the varia-
tions across CT scanner models are small.43,44 Thus,
our method may be used to provide normalized dose
and risk in the format of Eqs. 4 and 5 that are inde-
pendent of scanner models.
c If the process of creating a full-body computer model
from each patient’s clinical CT data can be fully auto-
mated, it would be possible to estimate patient-specific
dose and risk in real time immediately following a pa-
tient’s CT examinations. In this study, we used 80 mil-
lion photon histories 6.5 h user time to simulate each
CT scan of each patient to obtain relative dose errors of
less than 1% for any organ inside the scan coverage
and less than 3% for any organ outside of the scan
coverage. In fact, 
7 million photon histories 1 h
418 Li et al.: Patient-specific CT dose and risk: Application to patients 418user time were sufficient to achieve relative dose
errors of less than 1% for all organs in the scan
coverage and less than 10% for other organs. With
the implementation of GPU technology,45 the speed
of Monte Carlo simulations may soon meet the re-
quirements for real-time applications. Considering
the uncertainties associated with Monte Carlo simu-
lations point dose discrepancies of −17% to 13%
between simulation and measurement for helical
scans, see Ref. 47, it is possible that the dose dif-
ference among patients of similar body habitus is
smaller than or comparable to the uncertainties asso-
ciated with the Monte Carlo simulation. If future
studies show that is the case, there will be no need to
create a patient-specific model for every patient, and
the first two approaches can be used.
Our study has several limitations. First, both patients in
our study underwent fixed-tube-current examinations tube
current modulation was not the standard practice in 2006. If
the same patients were examined at our institution today,
tube-current-modulation techniques would have been used
with the maximum tube currents similar to the mA values in
Table I. Thus, the dose and risk to the two patients would
have been lower than that reported in Tables III and IV.
Second, the accuracy of our risk estimations is limited by the
accuracy/uncertainties of the current cancer risk models,22
which are largely based on the life-span studies of atomic-
bomb survivors and limited number of studies on occupa-
tional exposures. Furthermore, as the risk coefficients are
still statistical averages over many individuals of the same
gender and similar age, they cannot reflect individual vulner-
ability due to genetic factors. As such, the cancer risks we
reported do not represent the true risk of an individual from
his/her CT examination but rather our current best knowl-
edge of the potential risk to a patient from his/her CT exami-
nation, knowing the patient’s age and gender. Therefore, care
should be exercised when interpreting the risk results. Nev-
ertheless, the patient-specific risk information, as presented
by our study, represents a step forward beyond effective dose
toward personalized patient care.
V. CONCLUSION
It is possible to estimate patient-specific radiation dose
and cancer risk from CT examinations by combining a vali-
dated Monte Carlo program with patient-specific anatomical
models that are derived from the patients’ clinical CT data
and supplemented by transformed models of reference
adults. With the construction of a large library of patient-
specific computer models encompassing patients of all ages
and weight percentiles, dose and risk can be estimated for
any patient prior to or after a CT examination. Patient-
specific estimates can be included in a patient’s dosimetry
and medical record to track radiation exposure history from
medical imaging, serving as a basis from which to better
assess the cost-benefit ratio when making decisions about CT
Medical Physics, Vol. 38, No. 1, January 2011examinations in the clinical setting. They can further guide
the design and optimization of CT technologies and scan
protocols.
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